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Abstract
Cytomegalovirus (CMV) infection is a serious complication that may occur in the weeks or months following bone marrow transplantation.
However, both Ganciclovir and the CMV infection itself can cause marrow toxicity, notably neutropenia, that may consequently expose
these immunosuppressed patients to life-threatening bacterial and/or fungal infections. The aim of this retrospective study was to identify
factors associated with the occurrence of grade III–IV neutropenia among patients receiving pre-emptive Ganciclovir therapy after
allogeneic stem cell transplantation at our Institution. We identiﬁed 547 consecutive patients transplanted from January 2005 to June 2011
at our Institution. In all, 190 patients (35%) presented with CMV reactivation of whom 30 patients (5%) were excluded from the analysis
because they already had neutropenia at the time of reactivation. Finally, 160 (29%) patients were analysed. According to multivariate
analysis, at the time of treatment initiation, the risk factors signiﬁcantly associated with a grade III–IV Ganciclovir-related neutropenia
included a high viral load (hazard ratio (HR) = 2.68, 95% CI 1.25–5.737, p 0.01); an absolute neutrophil count >3000 was a protective factor
(HR = 0.26, 95% CI 0.125–0.545, p <0001) whereas serum creatinine >2 mg/dL was associated with higher Ganciclovir-related neutropenia
(HR = 2.4, 95% CI 1.11–5.17, p 0.002). This large analysis revealed three risk factors for Ganciclovir-related neutropenia among patients
with CMV reactivation after allogeneic stem cell transplantation; prompt identiﬁcation of patients at risk when antiviral therapy is started
may allow clinicians to adopt adequate preventive measures, so reducing the morbidity and mortality associated with CMV reactivation.
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Introduction
Cytomegalovirus (CMV) infection is a serious complication
that may occur in the weeks or months following allogeneic
stem cell transplantation (Allo-SCT) [1,2]. Therefore it must
be treated as soon as positive CMV reactivation is noticed:
pre-emptive therapy has been demonstrated to improve
survival among patients reactivating CMV after transplantation
[3,4]. However, Ganciclovir, as well as CMV infection itself,
pose a well-known marrow toxicity risk, notably neutropenia,
that may consequently expose these immunosuppressed
patients to other life-threatening bacterial and fungal infections
[5,6]. So far, only two studies have identiﬁed speciﬁc risk
factors and outcome predictors for Ganciclovir-related neu-
tropenia, ﬁnding low marrow cellularity between days 21 and
28, hyperbilirubinaemia >6 mg/dL during the ﬁrst 20 days,
serum creatinine >2 mg/L after day 21 and absolute neutrophil
count to be predictive factors [7,8]. However, transplantation
has evolved in recent years; especially because of the
introduction of reduced-intensity conditioning regimens and
supportive care [9,10]. The aim of the present analysis is to
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identifying risk factors for neutropenia among a large cohort of
patients treated with pre-emptive Ganciclovir who received
Allo-SCT at our Institution over the last 6 years.
Patients and Methods
This is a retrospective study on a cohort of 547 consecutive
patients receiving allotransplants from January 2005 to June
2011 at our Institution. Data collection was achieved by
retrieval of electronic patient records. The study was
approved by the Institut Paoli-Calmettes Institutional Board.
Diagnoses were haematological malignancies, aplastic anaemia
and metastatic solid tumours. Transplants were performed
using three sources: bone marrow, peripheral blood stem cells
and cord blood. Donors were HLA-matched siblings or
matched or mismatched unrelated donors. Myeloablative,
non-myeloablative and reduced-intensity conditioning regi-
mens were administered according to local guidelines or
established protocols [9,11,12].
GvHD prophylaxis and supportive care
Graft versus host disease (GvHD) prophylaxis consisted of
cyclosporin A in 334 patients (61%), cyclosporin A + myco-
phenolate mofetyl in 198 patients (36%), 11 patients (2%) were
free from any immunosuppressive therapy and mycophenolate
mofetyl was used alone in four patients (1%). Cyclosporin A
doses were adjusted to achieve blood levels between 150 and
250 ng/mL and to prevent renal dysfunction. Cyclosporin A
was tapered starting on day 90 if no GvHD appeared. The
main patient and transplant characteristics are shown in
Table 1.
Our protocol for providing supportive care was the same
throughout this time period. Prophylactic treatment against
Pneumocystis jirovecii and toxoplasmosis consisted of trimeth-
oprim-sulfamethoxazole (10 mg/kg/day trimethoprim) admin-
istered twice weekly. Patients also received daily oral
amoxicillin (500 mg 9 3/day) as prophylaxis against encapsu-
lated bacteria and oral valacyclovir (500 mg 9 2/day) as
prophylaxis against herpes simplex virus.
CMV monitoring and treatment
Serial weekly monitoring for CMV quantiﬁcation was done
using either pp65 antigen (between 2000 and 2009) or a
quantitative PCR assay on the whole blood (COBAS R, Roche
Diagnostics, Branchburg, NJ, USA; with a lower detection limit
of 30 copies/mL) (from 2009 to the present). Monitoring was
performed weekly initially, starting from transplantation until
day 90, and then every 4–8 weeks during the next 6 months. If
there was evidence of reactivation (pp65 >2 cells/200 000 or
PCR >1000 copies/mL), treatment was started with Ganciclo-
vir (5 mg/kg intravenous twice daily) for 2 weeks, provided
two consecutive PCRs performed 3 days apart became
negative. If the PCR was still positive after 2 weeks of
treatment, a maintenance therapy with Ganciclovir (5 mg/kg
intravenously once per day) for another 14 days was pro-
posed. CMV disease was diagnosed on demonstration of tissue
invasion in biopsy specimens or demonstration of a positive
CMV early antigen test on bronchoalveolar lavage, along with
clinical and radiological features consistent with CMV. Only
the ﬁrst episode of CMV reactivation or CMV disease was
taken into account.
Grade III neutropenia is deﬁned by an absolute neutrophil
count (ANC) between 500 and 1000/lL and a grade IV
neutropenia by an ANC <500/lL. (Table 1).
Objectives and statistical analysis
The principal objective of the study was to identify factors
associated with the occurrence of grade III–IV neutropenia
among patients receiving antiviral therapy due to CMV
reactivation. The following variables were analysed among
patients with CMV reactivation: initial replicating virus copies
(determined both by antigenaemia and PCR), time from
transplant to CMV reactivation, patient’s age, diagnosis, stem
cell source, conditioning regimen, serum creatinine, hyperbi-
lirubinaemia, absolute neutrophil count at CMV reactivation,
presence of GvHD at CMV reactivation, relapse or progres-
sive disease at CMV reactivation. These factors were then
correlated with grade III–IV neutropenia during antiviral
therapy. We considered values of PCR >5000 copies/mL and
antigenaemia >10 infected cells as a high viral load, to be
compared with lower values. Logistic regression was used
both for univariate and multivariate analyses. Patients with
grade III–IV neutropenia at the moment of CMV reactivation
were excluded from this analysis. Variables with p <0.20 were
then included in the multivariate analysis; only factors with
p <0.05 were retained in the ﬁnal model.
Secondarily, overall survival, transplant-related mortality
(TRM) and relapse/progression were analysed and compared
between patients who reactivated CMV versus those who did
not. As CMV reactivation is a post-transplant event, landmark
analysis was performed. Estimates of overall survival were
calculated by the Kaplan–Meier method with respective 95%
conﬁdence intervals, starting from day of transplant. TRM,
relapse/progression, CMV reactivation and grade III–IV neu-
tropenia were evaluated by cumulative incidence; relapse/
progression and TRM were considered competing events.
Death from any cause was considered as a competing event in
CMV reactivation and grade III–IV neutropenia analyses. The
SPSS v16.0 and R v2.12.2 programs were used.
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Results
A total of 547 patients were included in the analysis. One
hundred and ninety patients presented with CMV reactivation
(35%). Thirty patients were excluded from the analysis because
they already had neutropenia at the time of reactivation.
Finally, 160 patients were analysed. Solid tumours and
non-malignant haematological diseases represented a very
small proportion of transplant patients. A minority of patients
received T-depletion by anti-thymocyte globulin.
Peripheral blood stem cells were the main type of grafts
used. Eighty of 160 (50%) patients presented Ganciclo-
vir-related neutropenia, 39 patients had grade III neutropenia
and 41 patients had grade IV. The average time between the
introduction of Ganciclovir and the occurrence of neutropenia
was 35 days (range 2–216 days). All patients with grade III–IV
neutropenia (80 patients in all) received granulocyte col-
ony-stimulating factor until ANC recovered to >1000/lL for at
least three consecutive days. At CMV reactivation, median
antigenaemia was nine infected cells (range 9–969) and the
median number of copies according to PCR was 6149/mL
(range 995–2 228 620). The median number of days before
CMV reactivation was 42 (range 12–969). Eighty-eight percent
of all CMV reactivation had occurred by day 100 post-trans-
plant. The cumulative incidence of CMV reactivation, as shown
All patients
Patients with CMV
reactivation
Patients with
Ganciclovir-related
neutropenia p values
No. of patients 547 (100%) 190 (35%) 80 (42%) n.s
Median age at Allo-SCT (range) 51 (17–71) 51 (17–51) 51 (17–69) n.s
Disease n.s
AML 193 (35%) 55 (29%) 22 (28%)
NHL 98 (17.9%) 42 (22%) 21 (26%)
MM 63 (11.5%) 24 (13%) 8 (10%)
ALL 54 (9.8%) 22 (12%) 9 (11%)
MDS 33 (6%) 11 (6%) 3 (3.8%)
CLL 23 (4.2%) 10 (5%) 5 (6%)
Aplastic anaemia 12 (2.2%) 7 (4%) 3 (3.8%)
Hodgkin’s disease 23 (4.2%) 5 (3%) 2 (2.5%)
CML 13 (2.4%) 4 (2%) 2 (2.5%)
Breast cancer 7 (1.3%) 3 (2%) 2 (2.5%)
IM 12 (2.2%) 3 (1%) 1 (1.3%)
PNH 3 (0.5%) 2 (1%) 1 (1.3%)
CMML 4 (0.7%) 1 (0.5%) 1 (1.3%)
Waldenstrom 1 (0.2%) 1 (0.5%) 0 (0%)
PV 2 (0.4%) 0 (0%) 0 (0%)
Ovarian cancer 5 (0.9%) 0 (0%) 0 (0%)
Uterine cancer 1 (0.2%) 0 (0%) 0 (0%)
Conditioning n.s
MAC 30 (5.5%) 8 (4%) 3 (3.8%)
BOOST 10 (1.8%) 2 (1%) 64 (80%)
RIC 431 (78.8%) 154 (81%) 12 (15%)
RTC 76 (13.9%) 26 (14%) 1 (1.2%)
Prophylaxis of GvHD n.s
CSA 332 (60.7%) 111 (58%) 40 (50%)
CSA + MMF 202 (37%) 76 (40%) 38 (47.4%)
MMF 3 (0.5%) 2 (1%) 1 (1.3%)
None 10 (1.8%) 1 (0.5%) 1 (1.3%)
CMV serology Donors/Recipients n.s
Donor +/Recipient + 191 (35%) 69 (36%) 25 (31%)
Donor +/Recipient  156 (28.5%) 91 (48%) 41 (51%)
Donor /Recipient + 57 (10.4%) 3 (1.5%) 1 (1.3%)
Donor /Recipient  108 (20%) 9 (5%) 4 (5%)
Unknown 35 (6.4%) 18 (9.5%) 9 (11.2%)
Stem cell source n.s
PBSC 423 (77.3%) 142 (75%) 57 (72%)
CB 84 (15.3%) 33 (17%) 14 (17.5%)
BM 40 (7.4%) 15 (8%) 9 (11.5%)
T-cell depletion n.s
Yes 370 (67.6%) 110 (58%) 54 (67.5%)
No 177 (32.4%) 80 (42%) 26 (32.5%)
Donor type n.s
Related donor 301 (55%) 90 (47%) 40 (50%)
MUD 128 (23.4%) 49 (26%) 21 (26.3%)
MMUD 118 (21.6%) 51 (27%) 19 (23.7%)
GvHD n.s
GvHD grade 0/I 74 (13.5%) 22 (11.5%) 4 (5%)
GvHD grade II–IV 154 (28%) 75 (39.5%) 37 (46%)
None 319 (58.5%) 93 (49%) 39 (49%)
Allo-SCT, allogeneic stem cell transplantation; AML, acute myeloid leukaemia; NHL, non-Hodgkin lymphoma; ALL, acute
lymphoblastic leukaemia; PNH, paroxysmal nocturnal haemoglobinuria; CLL, chronic lymphoblastic leukaemia; CML,
chronic myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; MDS, myelodysplastic syndromes; IM, idiopathic
myeloﬁbrosis; PV, polycythaemia vera; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; RTC,
reduced toxicity regimen; PBSC, peripheral blood stem cell; CB, cord blood; MUD, matched unrelated donor; MMUD,
mismatched unrelated donor; CSA, cyclosporin; MMF, mycophenolate mofetil; GvHD, graft versus host disease.
TABLE 1. Patients and transplant
characteristics
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in Fig. 1, was 34% (95% CI 30–38%). CMV reactivation was
36% (69/191), 58% (91/156), and 5% (3/56) among donor/
patient pairs with positive/positive, positive/negative and
negative/positive CMV serostatus. Nine primary CMV infec-
tions were observed among donor/patient pairs with negative/
negative CMV serostatus. Twenty-seven patients (14%) devel-
oped a CMV disease (18 disseminated gastrointestinal colitis,
two pneumonitis and seven disseminated gastrointestinal and
lung disease).
In those 80 patients with Ganciclovir-related neutropenia,
20 patients (25%) developed concomitant bacterial infections,
and 16 patients (20%) developed concomitant invasive fungal
infections.
Risk factors for neutropenia
Upon univariate analysis, risk factors signiﬁcantly associated
with a grade III–IV Ganciclovir-related neutropenia at the time
of treatment initiation included a high viral load (hazard ratio
(HR) = 2.61, 95% CI 1.42–4.85, p 0.002); ANC >3000/lL was
a protective factor (HR = 0.32, 95% CI 0.17–0.63; p 0.001)
while serum creatinine over 2 mg/dL was associated with
higher Ganciclovir-related neutropenia (HR = 2.12, 95% CI
1.04–4.34; p 0.04). All other parameters studied were not
statistically signiﬁcant (Table 2a). Bilirubin could not be
analysed because only six patients presented with hyperbiliru-
binaemia.
All parameters statistically signiﬁcant in the univariate
analysis were still relevant upon multivariate analysis. Hence,
ANC >3000 is a protective factor, (HR = 0.26, 95% CI 0.125–
0.545, p <0001). Creatinine <2 mL/dL after 21 days was a risk
factor for Ganciclovir-related neutropenia (HR = 2.4, 95% CI
1.11–5.17, p 0.002) as well as a high viral load (HR = 2.68, 95%
CI 1.25–5.737, p 0.01; Table 2b).
CMV and transplant outcomes
Since 88% of CMV reactivation occurred within 100 days after
Allo-SCT, we chose a landmark day of +100. The analysis of
overall survival at 5 years revealed signiﬁcantly lower overall
survival in patients with CMV reactivation, 43% (32–54) versus
57% (46–68), respectively (p <0.0001; Fig. 2a).
We found a higher TRM at 5 years among patients who
developed CMV reactivation: 29% (21–36) versus 12% (8–17;
p 0.003). Therewas no signiﬁcant difference in the risk of relapse
in patients who reactivated CMV compared with those who did
not reactivate, 32% versus 34% (p value not signiﬁcant; Fig. 2b).
Discussion
Neutropenia following reactivation itself and/or antiviral
therapy may represent a potentially life-threatening complica-
tion because of the risk of bacterial or fungal infections,
especially in patients with concomitant GvHD who are
undergoing steroid treatment [13–16]. For this reason, we
decided to conduct a retrospective analysis of 547 consecutive
patients transplanted at our Institution, to identify risk factors
of neutropenia and potentially prevent this complication in
those patients at risk in the future.
In this large series of adult patients presenting with CMV
reactivation after Allo-SCT, we found patient age, serum CMV
load and ANC value at viral reactivation to be signiﬁcant
predictive factors of neutropenia [17–19]. CMV reactivation is
a well-known risk factor for mortality after transplantation
[20]. Pre-emptive therapy has been shown to improve survival
and monitoring of CMV levels is recommended in high-risk
patients [21].FIG. 1. Cumulative incidence of cytomegalovirus.
TABLE 2. (a) Univariate analysis; (b) multivariate analysis
Variables Hazard ratio 95% CI p
(a)
Patient’s age >55 years vs <55 years 1.39 0.78–2.48 0.27
Diagnosis 0.57
Conditioning 0.7 0.14–3.56 0.67
Donor type 0.55
ANC >3000 vs <3000 0.32 0.17–0.63 0.001
Creatinine >2 mg/dL after Day +
21 vs Creatinine <2 mg/dL
2.12 1.04–4.34 0.04
Hight viral load vs low viral load 2.61 1.42–4.85 0.002
GvHD Yes vs No 0.88 0.49–1.59 0.67
Progressive disease 1.61 0.84–3.10 0.15
(b)
ANC >3000 vs <3000 0.26 0.12–0.54 <0.0001
Creatinine >2 mg/dL after Day +
21 vs creatinine <2 mg/dL
2.4 1.11–5.17 0.002
High virus load vs low virus load 2.68 1.25–5.74 0.01
ANC, absolute neutrophil count.
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In addition, whenever possible, a CMV-negative donor is
chosen for CMV-negative patients to avoid viral reactivation
[18,20,22–24]. In this study, one clinical and two biological
variables were associated with higher risk of Ganciclo-
vir-related neutropenia; such variables can be easily identiﬁed
at the start of antiviral therapy and so may lead clinicians to
adopt adequate preventive measures (such as more attentive
and frequent monitoring, granulocyte colony-stimulating fac-
tor, prophylactic antibacterial therapy, etc.).
Our cumulative incidence of CMV reactivation was 35%
(190/547 patients), which is comparable with the article of
George et al. (39%) [24].
On the other hand, the difference from other study by Green
et al. could be related to the higher proportion of myeloablative
conditioning and also by a different deﬁnition of a CMV
reactivation (>500 copies/mL and >100 copies/mL in patients
receiving anti-thymocyte globulin and CAMPATH) [25].
Moreover, we also conﬁrmed in this study that CMV
reactivation is associated with inferior survival because of
higher TRM, and we cannot exclude the possibility that
Ganciclovir-related neutropenia could at least in part contrib-
ute to TRM. Many years ago, Salzberger et al. [7] and Boeckh
et al. [26] determined that low marrow cellularity between
days 21 and 28 is a risk factor for Ganciclovir-related
neutropenia. Moreover, in 2004, Tomonari et al. [8] showed
that incidence of Ganciclovir-related neutropenia in patients
with an ANC <1000 (250 and 500/lL) was signiﬁcantly lower
after Allo-SCT using cord blood cells in comparison with grafts
from bone marrow cells. When analysing these results in light
of the scientiﬁc literature, our study differs from previous ones
in many important respects. First, compared with the paper of
Salzberger et al. [7], who found that early liver dysfunction, an
increase in serum creatinine and low marrow cellularity were
risk factors for Ganciclovir-related neutropenia, in our study
conditioning was different because reduced-intensity condi-
tioning regimen transplants were used (81%), compared with
the above-mentioned study where only myeloablative condi-
tioning was used; this probably explains the low liver toxicity in
our patients, with bilirubin in the ﬁrst 20 days of transplan-
tation exceeding 6 mg/dL in only six patients (3.75%).
Second, our results regarding ANC <3000 as a risk factor
for Ganciclovir-related neutropenia are consistent with the
results of Tomonari et al. [8] and Salzberger et al. [7], who
consider marrow toxicity and low absolute neutrophil count
(<1000) as risk factors related to Ganciclovir neutropenia [7,8].
Third, the study of Tomonari et al. [8] was a comparative study
between cord blood and marrow transplantation whereas in
our study we compared all stem cell sources and did not ﬁnd
any signiﬁcant differences between the graft sources with
respect to Ganciclovir-related neutropenia (Table 1).
Fourth, in our study, 544 patients were included, which is
higher than in the previous studies (278 and 37 patients,
respectively). Finally, regarding the impact of renal failure on
Ganciclovir-related neutropenia, we can suppose that a poor
elimination of Ganciclovir leads to higher bone marrow
toxicity because of accumulation of Ganciclovir [27].
In conclusion, in this large analysis we could identify three
risk factors for Ganciclovir-related neutropenia among
patients with CMV reactivation after Allo-SCT; prompt
identiﬁcation of patients at risk when antiviral therapy is
started may allow physicians to adopt adequate preventive
measures; this could probably reduce the morbidity and
mortality associated with CMV reactivation, warranting further
prospective studies.
(a)
(b)
FIG. 2. (a) Overall survival. (b) treatment-related mortality and
relapse.
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